Harrow, Inc. (NASDAQ:HROW) Receives $71.14 Consensus Price Target from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have been assigned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $71.1429.

A number of research analysts have issued reports on HROW shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Cantor Fitzgerald cut their price objective on shares of Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Nomura lowered shares of Harrow to a “neutral” rating in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Harrow in a research note on Thursday.

Institutional Investors Weigh In On Harrow

Institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its position in Harrow by 102.5% in the first quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock worth $261,000 after buying an additional 4,967 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after acquiring an additional 790 shares in the last quarter. Strs Ohio acquired a new position in shares of Harrow in the 1st quarter worth $149,000. Los Angeles Capital Management LLC raised its position in shares of Harrow by 68.0% during the second quarter. Los Angeles Capital Management LLC now owns 28,779 shares of the company’s stock worth $879,000 after purchasing an additional 11,650 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Harrow by 4.7% during the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after purchasing an additional 36,724 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Performance

Shares of HROW stock opened at $33.28 on Friday. Harrow has a 12-month low of $20.85 and a 12-month high of $54.85. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -195.75 and a beta of 0.05. The business has a 50 day simple moving average of $44.53 and a 200 day simple moving average of $43.45. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.06.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.